For the Inventor, By the Inventor

Enter assignee name

Newron Pharmaceuticals S.p.a.

Calculating rank

USPTO Granted Patents = 40

% Expired Patents = 12.5

CIPO Patents = 10

EPO Patents = 18

Trademarks = 2

Forward Citations = 59

Loading Chart...

Loading Chart...

54 inventors (with patents filed for the assignee):

Patricia Salvati (27 out of 47 patents)

Alessandra Restivo (13 out of 13 patents)

Piero Melloni (11 out of 47 patents)

4. Emanuela Izzo (11 out of 11 patents)

5. Cibele Sabido-David (11 out of 11 patents)

6. Florian Thaler (10 out of 15 patents)

7. Elena Colombo (9 out of 9 patents)

8. Luca Benatti (9 out of 12 patents)

9. Simona Francisconi (8 out of 8 patents)

10. Elena Barbanti (8 out of 9 patents)

11. Ruggero Fariello (7 out of 9 patents)

12. Laura Faravelli (7 out of 7 patents)

13. Carla Caccia (7 out of 16 patents)

14. Cibele Maria Sabido David (5 out of 5 patents)

15. Paolo Pevarello (4 out of 49 patents)

Core Competencies:

Sodium Channel Modulators

Cognitive Disorders

Parkinson's Disease

Alpha-Aminoamide Derivatives

Pharmaceutical Composition

High Purity Compounds

Analgesic Agents

Addictive Disorders

Restless Legs Syndrome

Antimigraine Agents

Fluorinated Derivatives

Substituted Compounds

40 patents: Sort by Forward Citations

1. 12291495 - Process for the production of substituted 2-[2-(phenyl)ethylamino] alkaneamide derivatives (2025-05-06),

2. 12134589 - Process for the production of substituted 2-[2-(phenyl) ethylaminojalkaneamide derivatives (2024-11-05),

3. 9856207 - Process for the production of ralfinamide salts substantially free from impurities having genotoxic effects (2018-01-02),

4. 9603832 - Substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives and their use as sodium and/or calcium channel modulators (2017-03-28),

5. 9585869 - Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators (2017-03-07),

6. 9505708 - Process for the production of ralfinamide salts substantially free from impurities having genotoxic effects (2016-11-29),

7. 9492410 - Methods for treatment of Parkinson's disease (2016-11-15),

8. 9474739 - Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators (2016-10-25),

9. 9474738 - Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators (2016-10-25),

10. 9474737 - Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators (2016-10-25),

11. 9447029 - Fluorinated arylalkylaminocarboxamide derivatives (2016-09-20),

12. 9248116 - Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators (2016-02-02),

13. 9051240 - Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators (2015-06-09),

14. 8901176 - Methods for treatment of Parkinson's disease (2014-12-02),

15. 8846763 - High purity 2-[4-(3- or 2-fluorobenzyloxy)benzylamino] propanamides and methods of use thereof (2014-09-30),

Company Overview

Newron Pharmaceuticals S.p.a., based in Bresso, Italy, specializes in the development of innovative therapies for neurological and psychiatric disorders. The company focuses on sodium and calcium channel modulators, as well as alpha-aminoamide derivatives, targeting conditions such as Parkinson's disease, cognitive disorders, and addictive disorders. Newron is dedicated to advancing pharmaceutical compositions that address unmet medical needs, leveraging its expertise in complex neurological conditions to improve patient outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

40 Patents

#1 in Bresso

#237 in Italy

#17,122 in the World

Newron Pharmaceuticals S.p.a.

Forward Citations = 59

54 inventors:

Patricia Salvati (27 out of 47 patents)

Alessandra Restivo (13 out of 13 patents)

Piero Melloni (11 out of 47 patents)

4. Emanuela Izzo (11 out of 11 patents)

5. Cibele Sabido-David (11 out of 11 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Newron Pharmaceuticals S.p.a.. Retrieved from https://idiyas.com/company/newron-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…